Skip to main content

Articles

Page 1 of 61

  1. Calcitonin gene-related peptide (CGRP) antagonizing drugs represents the most important advance in migraine therapy for decades. However, these new drugs are only effective in 50–60% of patients. Recent studie...

    Authors: Song Guo, Charlotte Ernstsen, Anders Hay-Schmidt, Messoud Ashina, Jes Olesen and Sarah Louise Christensen
    Citation: The Journal of Headache and Pain 2022 23:155
  2. The definitive pathogenic mechanisms underlying chronic migraine (CM) remain unclear. Mounting evidence from functional and structural magnetic resonance imaging (MRI) studies suggests that the caudate nucleus...

    Authors: Ziyu Yuan, Wei Wang, Xueyan Zhang, Xiaoyan Bai, Hefei Tang, Yanliang Mei, Peng Zhang, Dong Qiu, Xue Zhang, Yaqing Zhang, Xueying Yu, Binbin Sui and Yonggang Wang
    Citation: The Journal of Headache and Pain 2022 23:154
  3. The multinational phase 3b DELIVER trial was designed to evaluate the efficacy and safety of eptinezumab for migraine prevention in patients with prior preventive treatment failures across 17 countries. In the...

    Authors: Piero Barbanti, Peter J. Goadsby, Giorgio Lambru, Anders Ettrup, Cecilie Laurberg Christoffersen, Mette Krog Josiassen, Ravinder Phul and Bjørn Sperling
    Citation: The Journal of Headache and Pain 2022 23:153
  4. Hypothalamus is a key region in migraine attacks. In addition, women are disproportionately affected by migraine. The calcitonin gene-related peptide (CGRP) system is an important key player in migraine pathop...

    Authors: Aida Maddahi, Lars Edvinsson and Karin Warfvinge
    Citation: The Journal of Headache and Pain 2022 23:152
  5. Cluster headache and migraine are regarded as distinct primary headaches. While cluster headache and migraine differ in multiple aspects such as gender-related and headache specific features (e.g., attack dura...

    Authors: Mohammad Al-Mahdi Al-Karagholi, Kuan-Po Peng, Anja Sofie Petersen, Irene De Boer, Gisela M. Terwindt and Messoud Ashina
    Citation: The Journal of Headache and Pain 2022 23:151
  6. Headache recurrence is a common feature of acute therapies, whether approved or still in development, and continues to be a significant problem for both the patient and the clinician. Further complicating this...

    Authors: Stewart J. Tepper, Jessica Ailani, Sutapa Ray, Joe Hirman, Stephen B. Shrewsbury and Sheena K. Aurora
    Citation: The Journal of Headache and Pain 2022 23:148
  7. Cluster headache is a highly debilitating neurological disorder with considerable inter-ethnic differences. Genome-wide association studies (GWAS) recently identified replicable genomic loci for cluster headac...

    Authors: Shih-Pin Chen, Chia-Lin Hsu, Yen-Feng Wang, Fu-Chi Yang, Ting-Huei Chen, Jia-Hsin Huang, Li-Ling Hope Pan, Jong-Ling Fuh, Hsueh-Chen Chang, Yi-Lun Lee, Hung-Ching Chang, Ko-Han Lee, Yu-Chuan Chang, Cathy Shen-Jang Fann and Shuu-Jiun Wang
    Citation: The Journal of Headache and Pain 2022 23:147
  8. DRAGON was a phase 3, randomised, double-blind, placebo-controlled study which evaluated the efficacy and safety of erenumab in patients with chronic migraine (CM) from Asia not adequately represented in the g...

    Authors: Shengyuan Yu, Byung-Kun Kim, Hebo Wang, Jiying Zhou, Qi Wan, Tingmin Yu, Yajun Lian, Michal Arkuszewski, Laurent Ecochard, Shihua Wen, Fangfang Yin, Zheng Li, Wendy Su and Shuu-Jiun Wang
    Citation: The Journal of Headache and Pain 2022 23:146
  9. Trigeminal neuralgia is a severe facial pain disorder. Microvascular decompression is first choice surgical treatment of patients with classical TN. There exist few prospective studies with an independent eval...

    Authors: Anne Sofie Schott Andersen, Tone Bruvik Heinskou, Per Rochat, Jacob Bertram Springborg, Navid Noory, Emil Andonov Smilkov, Lars Bendtsen and Stine Maarbjerg
    Citation: The Journal of Headache and Pain 2022 23:145
  10. In Woldeamanuel and Oliveira (2022)’s article about the efficacy of exercise in the treatment of migraine, the ranking of the efficacy of strength training (mean difference, − 3.55), aerobic exercise (mean dif...

    Authors: Junhee Han and Soo-Jin Cho
    Citation: The Journal of Headache and Pain 2022 23:144

    The original article was published in The Journal of Headache and Pain 2022 23:134

  11. Deficient endogenous pain modulation has been implicated in the development and exacerbation of chronic orofacial pain. To date, relatively little is known regarding the function of the endogenous pain modulat...

    Authors: Christelle Gremeau-Richard, Paul Pionchon, Aurélien Mulliez, Christian Dualé and Radhouane Dallel
    Citation: The Journal of Headache and Pain 2022 23:143
  12. The fully human monoclonal antibody erenumab, which targets the calcitonin gene-related peptide (CGRP) receptor, was licensed in Switzerland in July 2018 for the prophylactic treatment of migraine.

    Authors: Andreas R. Gantenbein, Reto Agosti, Christian P. Kamm, Gunther Landmann, Niklaus Meier, Gabriele Susanne Merki-Feld, Jens A. Petersen, Heiko Pohl, Philippe Ryvlin, Christoph J. Schankin, Dragana Viceic, Chiara Zecca, Elisabeth Schäfer, Ina Meyer and Michael E. Arzt
    Citation: The Journal of Headache and Pain 2022 23:142
  13. HER-MES was the first head-to-head, phase 4 trial to assess the tolerability and effectiveness of erenumab against standard of care treatment (topiramate). This post hoc analysis compared the efficacy of erenu...

    Authors: Marc Ehrlich, Christian Hentschke, Christian Sieder, Monika Maier-Peuschel and Uwe Reuter
    Citation: The Journal of Headache and Pain 2022 23:141
  14. Observational studies on the prevalence of premonitory symptoms in people with migraine, preceding the headache pain (or aura) phase, have shown conflicting results. We conducted a systematic review and meta-a...

    Authors: Anna K. Eigenbrodt, Rune Häckert Christensen, Håkan Ashina, Afrim Iljazi, Casper Emil Christensen, Timothy J. Steiner, Richard B. Lipton and Messoud Ashina
    Citation: The Journal of Headache and Pain 2022 23:140
  15. Controlled and real-world evidence have demonstrated the efficacy of calcitonin gene related peptide (CGRP) monoclonal antibodies (MABs) in migraine. However, data on the over-one-year sustained effectiveness ...

    Authors: Anna P. Andreou, Matteo Fuccaro, Bethany Hill, Madeleine Murphy, Valeria Caponnetto, Rachael Kilner and Giorgio Lambru
    Citation: The Journal of Headache and Pain 2022 23:139
  16. The identification of predictors of response to antiCGRP mAbs could favor tailored therapies and personalized treatment plans. This study is aimed at investigating predictors of ≥ 50%, ≥ 75% and 100% response ...

    Authors: Piero Barbanti, Gabriella Egeo, Cinzia Aurilia, Claudia Altamura, Florindo d’Onofrio, Cinzia Finocchi, Maria Albanese, Marco Aguggia, Renata Rao, Maurizio Zucco, Fabio Frediani, Massimo Filippi, Roberta Messina, Sabina Cevoli, Antonio Carnevale, Giulia Fiorentini…
    Citation: The Journal of Headache and Pain 2022 23:138
  17. Short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT) and short-lasting unilateral neuralgiform headache attacks with cranial autonomic symptoms (SUNA) have not...

    Authors: Shuhua Zhang, Ya Cao, Fanhong Yan, Sufen Chen, Wei Gui, Dongmei Hu, Huanxian Liu, Hongjin Li, Rongce Yu, Dan Wei, Xiaolin Wang, Rongfei Wang, Xiaoyan Chen, Mingjie Zhang, Ye Ran, Zhihua Jia…
    Citation: The Journal of Headache and Pain 2022 23:137
  18. Cardiac cephalalgia is an unusual condition that occurs during an episode of myocardial ischemia. Information about cardiac cephalalgia is scarce and its characteristics and physiopathology remain unclear. Our...

    Authors: María Pilar Navarro-Pérez, Elena Bellosta-Diago, Jes Olesen and Sonia Santos-Lasaosa
    Citation: The Journal of Headache and Pain 2022 23:136
  19. To ascertain whether intravenous infusion of calcitonin gene-related peptide (CGRP) can induce migraine-like headache in people with persistent post-traumatic headache attributed to mild traumatic brain injury...

    Authors: Håkan Ashina, Afrim Iljazi, Haidar M. Al-Khazali, Thien Phu Do, Anna K. Eigenbrodt, Eigil L. Larsen, Amalie M. Andersen, Kevin J. Hansen, Karoline B. Bräuner, Basit Ali Chaudhry, Casper E. Christensen, Faisal Mohammad Amin and Henrik W. Schytz
    Citation: The Journal of Headache and Pain 2022 23:135
  20. Multiple clinical trials with different exercise protocols have demonstrated efficacy in the management of migraine. However, there is no head-to-head comparison of efficacy between the different exercise inte...

    Authors: Yohannes W. Woldeamanuel and Arão B. D. Oliveira
    Citation: The Journal of Headache and Pain 2022 23:134

    The Comment to this article has been published in The Journal of Headache and Pain 2022 23:144

  21. Triptans are migraine-specific acute treatments. A well-accepted definition of triptan failure is needed in clinical practice and for research. The primary aim of the present Consensus was to provide a definit...

    Authors: Simona Sacco, Christian Lampl, Faisal Mohammad Amin, Mark Braschinsky, Christina Deligianni, Derya Uludüz, Jan Versijpt, Anne Ducros, Raquel Gil-Gouveia, Zaza Katsarava, Paolo Martelletti, Raffaele Ornello, Bianca Raffaelli, Deirdre M. Boucherie, Patricia Pozo-Rosich, Margarita Sanchez-del-Rio…
    Citation: The Journal of Headache and Pain 2022 23:133
  22. Galcanezumab of 300 mg monthly is the FDA approved preventive medication for cluster headache (CH) during the cluster period. Compared to the 120 mg galcanezumab syringe for the treatment of migraines, the 100...

    Authors: Heejung Mo, Byung-Kun Kim, Heui-Soo Moon and Soo-Jin Cho
    Citation: The Journal of Headache and Pain 2022 23:132
  23. Migraine aura is a transient, fully reversible visual, sensory, or other central nervous system symptom that classically precedes migraine headache. This study aimed to investigate ce...

    Authors: Tong Fu, Lindong Liu, Xiaobin Huang, Di Zhang, Yujia Gao, Xindao Yin, Hai Lin, Yongming Dai and Xinying Wu
    Citation: The Journal of Headache and Pain 2022 23:131
  24. To identify and validate the neural signatures of resting-state oscillatory connectivity for chronic migraine (CM), we used machine learning techniques to classify patients with CM from healthy controls (HC) a...

    Authors: Fu-Jung Hsiao, Wei-Ta Chen, Li-Ling Hope Pan, Hung-Yu Liu, Yen-Feng Wang, Shih-Pin Chen, Kuan-Lin Lai, Gianluca Coppola and Shuu-Jiun Wang
    Citation: The Journal of Headache and Pain 2022 23:130
  25. Headache medicine is largely based on detailed history taking by physicians analysing patients’ descriptions of headache. Natural language processing (NLP) structures and processes linguistic data into quantif...

    Authors: Nicolas Vandenbussche, Cynthia Van Hee, Véronique Hoste and Koen Paemeleire
    Citation: The Journal of Headache and Pain 2022 23:129
  26. Chronic migraine is a common and highly disabling disorder. Functional MRI has indicated that abnormal brain region activation is linked with chronic migraine. Drugs targeting the calcitonin gene-related pepti...

    Authors: Shouyi Wu, Xiao Ren, Chenlu Zhu, Wei Wang, Kaibo Zhang, Zhilei Li, Xuejiao Liu and Yonggang Wang
    Citation: The Journal of Headache and Pain 2022 23:128
  27. Migraine is a highly prevalent disorder with significant economical and personal burden. Despite the development of effective therapeutics, the causes which precipitate migraine attacks remain elusive. Clinica...

    Authors: Olivia Grech, Matilde Sassani, Gisela Terwindt, Gareth G. Lavery, Susan P. Mollan and Alexandra J. Sinclair
    Citation: The Journal of Headache and Pain 2022 23:127
  28. The migraine premonitory phase is characterized in part by increased thirst, urination and yawning. Imaging studies show that the hypothalamus is activated in the premonitory phase. Stress is a well know migra...

    Authors: Caroline M. Kopruszinski, Robson Vizin, Moe Watanabe, Ashley L. Martinez, Luiz Henrique Moreira de Souza, David W. Dodick, Frank Porreca and Edita Navratilova
    Citation: The Journal of Headache and Pain 2022 23:126
  29. Migraine affects a significant fraction of the world population, yet its etiology is not completely understood. In vitro results highlighted thalamocortical and intra-cortical glutamatergic synaptic gain-of-fu...

    Authors: Nicolò Meneghetti, Chiara Cerri, Eleonora Vannini, Elena Tantillo, Angelita Tottene, Daniela Pietrobon, Matteo Caleo and Alberto Mazzoni
    Citation: The Journal of Headache and Pain 2022 23:125
  30. In disease areas with ‘soft’ outcomes (i.e., the subjective aspects of a medical condition or its management) such as migraine or depression, extraction and validation of real-world evidence (RWE) from electro...

    Authors: Nada A. Hindiyeh, Daniel Riskin, Kimberly Alexander, Roger Cady and Steven Kymes
    Citation: The Journal of Headache and Pain 2022 23:124
  31. In Italy, monoclonal antibodies targeting the CGRP pathway are subsidized for the preventive treatment of high frequency and chronic migraine (CM) in patients with a MIgraine Disability ASsessment (MIDAS) scor...

    Authors: Roberto De Icco, Gloria Vaghi, Marta Allena, Natascia Ghiotto, Elena Guaschino, Daniele Martinelli, Lara Ahmad, Michele Corrado, Federico Bighiani, Federica Tanganelli, Sara Bottiroli, Francescantonio Cammarota, Grazia Sances and Cristina Tassorelli
    Citation: The Journal of Headache and Pain 2022 23:123
  32. Chronic migraine is a common neurovascular brain disorder with substantial economic costs. We performed a systematic review to identify economic evaluations of pharmacological treatments for adults with chroni...

    Authors: Saval Khanal, Martin Underwood, Seyran Naghdi, Anna Brown, Callum Duncan, Manjit Matharu and Hema Mistry
    Citation: The Journal of Headache and Pain 2022 23:122
  33. To study the impact of chronic migraine (CM) on the cognition and quality of life (QoL) of patients in the interictal period, and to analyse the degree of reversibility of any observed alterations following th...

    Authors: Cristina González-Mingot, Anna Gil-Sánchez, Marc Canudes-Solans, Silvia Peralta-Moncusi, Maria José Solana-Moga and Luis Brieva-Ruiz
    Citation: The Journal of Headache and Pain 2022 23:121
  34. Serum levels of Calcitonin Gene-Related Peptide (CGRP)-like immunoreactivity (CGRP-LI) in migraine patients before and after starting treatment with erenumab were measured to evaluate the association with clin...

    Authors: Simone de Vries Lentsch, Ingrid M. Garrelds, A. H. Jan Danser, Gisela M. Terwindt and Antoinette MaassenVanDenBrink
    Citation: The Journal of Headache and Pain 2022 23:120
  35. The thalamus plays a crucial role in transmitting nociceptive information to various cortical regions involving migraine-related allodynia and photophobia. Abnormal structural and functional alterations relate...

    Authors: Ying Yang, Huang Xu, Ziru Deng, Wenwen Cheng, Xiuxiu Zhao, Yan Wu, Yuhua Chen, Gui Wei and Ying Liu
    Citation: The Journal of Headache and Pain 2022 23:119
  36. The Global Campaign against Headache collects data from children (6–11 years) and adolescents (12–17) to inform health and education policies and contribute to the Global Burden of Disease (GBD) study. This su...

    Authors: Nfwama Kawatu, Somwe Wa Somwe, Ornella Ciccone, Misheck Mukanzu, Derya Uluduz, Tayyar Şaşmaz, Bengü Nehir Buğdaycı Yalçın, Christian Wöber and Timothy J. Steiner
    Citation: The Journal of Headache and Pain 2022 23:118
  37. This study aimed to explore the central mechanism of classical trigeminal neuralgia (CTN) by analyzing the static amplitude of low-frequency fluctuation (sALFF) and dynamic amplitude of low-frequency fluctuati...

    Authors: Xiuhong Ge, Luoyu Wang, Lei Pan, Haiqi Ye, Xiaofen Zhu, Sandra Fan, Qi Feng, Wenhua Yu and Zhongxiang Ding
    Citation: The Journal of Headache and Pain 2022 23:117
  38. The relative effects of monoclonal antibody against calcitonin gene-related peptide (CGRP) or its receptor for adult migraine patients with prior treatment failure remains uncertain. Therefore, this study syst...

    Authors: Xing Wang, Dingke Wen, Qiang He, Chao You and Lu Ma
    Citation: The Journal of Headache and Pain 2022 23:105
  39. Patients with chronic migraine (CM) treated with eptinezumab in the PROMISE-2 trial achieved greater reductions in migraine and headache frequency, impact, and acute headache medication (AHM) use than did pati...

    Authors: Robert P. Cowan, Michael J. Marmura, Hans-Christoph Diener, Amaal J. Starling, Jack Schim, Joe Hirman, Thomas Brevig and Roger Cady
    Citation: The Journal of Headache and Pain 2022 23:115
  40. Trigeminal neuralgia is an episodic severe neuralgic pain and can be managed both medically and surgically. If possible, this should be directed by a Multidisciplinary Team (MDT) of specialised surgeons, physi...

    Authors: Sanjeet Singhota, Nana Tchantchaleishvili, Jianhua Wu, Ludvic Zrinzo, Lewis Thorne, Harith Akram and Joanna M. Zakrzewska
    Citation: The Journal of Headache and Pain 2022 23:114
  41. Migraine is a primary headache with genetic susceptibility, but the pathophysiological mechanisms are poorly understood, and it remains an unmet medical need. Earlier we demonstrated significant differences in...

    Authors: Timea Aczél, Bettina Benczik, Bence Ágg, Tamás Körtési, Péter Urbán, Witold Bauer, Attila Gyenesei, Bernadett Tuka, János Tajti, Péter Ferdinandy, László Vécsei, Kata Bölcskei, József Kun and Zsuzsanna Helyes
    Citation: The Journal of Headache and Pain 2022 23:113
  42. Migraine is the second leading cause of disability worldwide. Although many preventive treatments reduce migraine frequency and severity, it is unclear whether these treatments reduce migraine-related disabili...

    Authors: Peter McAllister, Joshua M. Cohen, Verena Ramirez Campos, Xiaoping Ning, Lindsay Janka and Steve Barash
    Citation: The Journal of Headache and Pain 2022 23:112
  43. It is well known that the course of migraine is influenced by comorbidities and that individual psychological characteristics may impact on the disease. Proper identification of psychological factors that are ...

    Authors: Francesca Pistoia, Federico Salfi, Gennaro Saporito, Raffaele Ornello, Ilaria Frattale, Giulia D’Aurizio, Daniela Tempesta, Michele Ferrara and Simona Sacco
    Citation: The Journal of Headache and Pain 2022 23:110
  44. More than 2/3 of children and adolescents in Germany regularly suffer from headaches. Headache-related limitations in everyday life, school drop-out and educational impairment are common. Structured therapy pr...

    Authors: Hanna Sobe, Matthias Richter, Reinhard Berner, Maja von der Hagen, Antje Hähner, Ingo Röder, Thea Koch, Rainer Sabatowski, Anna Klimova and Gudrun Gossrau
    Citation: The Journal of Headache and Pain 2022 23:109
  45. Studies investigating the association between migraine and dementia have reported inconsistent findings. This study aimed to evaluate whether patients with migraine have an increased risk of dementia compared ...

    Authors: Kyungduk Hurh, Sung Hoon Jeong, Seung Hoon Kim, Suk-Yong Jang, Eun-Cheol Park and Sung-In Jang
    Citation: The Journal of Headache and Pain 2022 23:108
  46. Insula plays an integrating role in sensory, affective, emotional, cognitive and autonomic functions in migraine, especially in migraine with aura (MA). Insula is functionally divided into 3 subregions, the do...

    Authors: Cédric Gollion, Fleur Lerebours, Federico Nemmi, Germain Arribarat, Fabrice Bonneville, Vincent Larrue and Patrice Péran
    Citation: The Journal of Headache and Pain 2022 23:106